Answers are grounded in this paper and cite their sources.
Gavi supports countries to introduce typhoid conjugate vaccine (TCV) with catch-up campaigns. Available TCVs are highly efficacious, equity-focused, and critical to curbing the expansion of antimicrobial resistance. Four Gavi-supported countries have introduced TCVs since 2018. In the wake of the COVID-19 emergency, momentum is building to scale up TCV introduction worldwide, supported by global partners and Gavi's funding for improved typhoid diagnostics.
No takes yet. Share an insight, caveat, or question.
Hampton et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: